Home > News > Starpharma Pooled Development - half year report and accounts
February 25th, 2004
Starpharma Pooled Development - half year report and accounts
The results for the half year include a 42% reduction in the operating loss of the economic entity during the period, compared with the corresponding period of the previous year. Whilst part of this improvement has resulted from the successful conversion of the former controlled entity Dendritic Nanotechnologies Ltd to a US incorporated associated entity (Dendritic Nanotechnologies, Inc), two thirds of the savings are attributable to reductions in expenditure by the Australian group, as set out in the report.
Harris & Harris Group Reports Financial Statements as of September 30, 2014 November 11th, 2014
Harris & Harris Group to Host Conference Call on Third Quarter 2014 Financial Results on November 12, 2014 November 3rd, 2014
Aspen Aerogels, Inc. Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 October 17th, 2014
Nanometrics to Announce Third Quarter Financial Results on October 28, 2014 October 8th, 2014